Vincerx Pharma (VINC) Stock Price, News & Analysis

Company Overview

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Key Stats

• Today's Range: $0.18 to $0.22
• 50-Day Range: $0.19 to $0.41
• 52-Week Range: $0.18 to $9.37
• Volume: 676,844 shs
• Average Volume: 673,799 shs
• Market Capitalization: $7.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Buy

Vincerx Pharma Stock Analysis - MarketRank™

Vincerx Pharma scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vincerx Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vincerx Pharma are expected to grow in the coming year, from ($0.50) to ($0.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vincerx Pharma is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vincerx Pharma is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vincerx Pharma has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.19% of the outstanding shares of Vincerx Pharma have been sold short.

Short Interest Ratio / Days to Cover

Vincerx Pharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vincerx Pharma has recently increased by 22.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vincerx Pharma does not currently pay a dividend.

Dividend Growth

Vincerx Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.19% of the outstanding shares of Vincerx Pharma have been sold short.

Short Interest Ratio / Days to Cover

Vincerx Pharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vincerx Pharma has recently increased by 22.57%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for VINC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vincerx Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VINC Stock Analysis - Frequently Asked Questions

How have VINC shares performed this year?

Vincerx Pharma's stock was trading at $1.18 at the beginning of the year. Since then, VINC stock has decreased by 82.2% and is now trading at $0.21.
View the best growth stocks for 2024 here.

How were Vincerx Pharma's earnings last quarter?

Vincerx Pharma, Inc. (NASDAQ:VINC) announced its earnings results on Thursday, August, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.12.

How do I buy shares of Vincerx Pharma?

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Vincerx Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vincerx Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 12/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VINC
• CUSIP: N/A
• CIK: 1796129
• Web: vincerapharma.com
• Phone: 650-800-6676
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.00
• High Stock Price Target: $2.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +852.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-40,160,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -248.33%
• Return on Assets: -132.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.17
• Quick Ratio: 2.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 33,651,000
• Free Float: 27,784,000
• Market Cap: $7.07 million
• Optionable: Not Optionable
• Beta: 1.48